Track topics on Twitter Track topics that are important to you
MiMedx® is the global premier processor, marketer, and distributor of human amniotic tissue. MiMedx® has distributed over 130,000 amniotic tissue grafts worldwide and achieved profound clinical outcomes in multiple therapeutic areas including ophthalmology, spine, chronic wounds, dental, orthopedic surgery, sports medicine, and urology. Over 50,000 of those amniotic tissue grafts were delivered in 2012 alone. With this groundbreaking human tissue offering that promotes bioactive healing, MiMedx® believes its unmatched knowledge and superior processing of amniotic tissue strategically positions the Company to become the leader in regenerative medicine.
The Company’s patent protected PURION® Process is the foundation of the MiMedx® AmnioFix® and EpiFix® products that serve to regenerate damaged or diseased tissues by delivering human extracellular matrix components, essential growth factors, and specialized mediating cytokines. AmnioFix® and EpiFix® reduce inflammation, reduce scar tissue formation, and enhance soft tissue healing. The Company’s proprietary PURION® Process dry preserves human amniotic membrane tissue, resulting in minimally manipulated tissue products that address numerous serious unmet medical needs requiring tissue regeneration or healing inside and outside the body. Through the Company’s unique process for dehydrating human amniotic tissues, improved clinical outcomes, increased patient quality of life, and reduced financial burden to the healthcare system are achieved.
MiMedx® obtains human amniotic membrane tissue that would otherwise be discarded through its placenta donation program. The “Give the Gift of Healing” placenta donation program allows mothers, delivering healthy babies by planned Caesarean section, to donate their placentas to MiMedx® which would otherwise be discarded by the hospital as medical waste. The MiMedx® staff and all of our resources are dedicated to handling, processing, and delivering the donated tissues to patients. The PURION® processed tissues are safe, effective, and minimally manipulated allografts that are intended for homologous use.
The MiMedx® allografts produced from the Company’s proprietary PURION® Process for amniotic membrane tissue can be stored at room temperature for five years without the need for refrigeration or freezing. The grafts can be utilized right out of the package without a complicated thawing process. These critical qualities of the MiMedx® allografts allow hospitals, clinics, and surgeons to immediately provide the appropriate treatment while effectively manage their inventory of allografts.
MiMedx® is dedicated to the development and support of thoughtful and effective philanthropic programs to help those in underserved medical areas in need of healing.
Source: http://mimedx.com/ (June 11th 2013)
1775 West Oak Commons Ct. NE
NewsMiMedx signs definitive agreement to divest Stability Biologics subsidiary as part of company's strategic focus on biopharma. MiMedx says it expects to have better ROI opportunities in biopharma c...
The recent announcement by the Company to transition into a biopharmaceutical company was an impetus for this divestiture initiative. Acquired by MiMedx in January 2016 Read more...
Based on exceptional interim results, in late June, MiMedx submitted a summary results amendment along with a formal request to the FDA for closure and Read more...
MiMedx Group Inc. is divesting its Stability Biologics LLC subsidiary to former Stability shareholders.
The osteoarthritis clinical trial will study MiMedx's AmnioFix® Injectable in a Phase 2, prospective, double-blinded, randomized controlled trial of the micronized dehydrated human amnion/chorion...
The Achilles Tendonitis clinical trial will study MiMedx's AmnioFix® Injectable in a Phase 3, Prospective, Double Blinded, Randomized Controlled Trial of the Micronized dHACM Injection Read more....
MARIETTA, Ga., June 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue al...
MARIETTA, Ga., Oct. 4, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants pro...
MiMedx® delivers innovative bioactive healing products for tissue regeneration MiMedx® is the global premier processor, marketer, and distributor of human amniotic tissue. MiMedx® has ...
We have published hundreds of MiMedx, Inc. news stories on BioPortfolio along with dozens of MiMedx, Inc. Clinical Trials and PubMed Articles about MiMedx, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MiMedx, Inc. Companies in our database. You can also find out about relevant MiMedx, Inc. Drugs and Medications on this site too.
Dentistry is the study, management and treatment of diseases and conditions affecting the mouth, jaw, teeth and their supporting tissues (Oxford Medical Dictionary) The work of a dentist ranges from regular patient check-up to orthodontics and surgery....
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...